Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective

BACKGROUND: The aim of this study was to project health-economic outcomes relevant to the German setting for the addition of pioglitazone to existing treatment regimens in patients with type 2 diabetes, evidence of macrovascular disease and at high risk of cardiovascular events. METHODS: Event rates...

Descripción completa

Detalles Bibliográficos
Autores principales: Scherbaum, Werner A, Goodall, Gordon, Erny-Albrecht, Katrina M, Massi-Benedetti, Massimo, Erdmann, Erland, Valentine, William J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2688482/
https://www.ncbi.nlm.nih.gov/pubmed/19416529
http://dx.doi.org/10.1186/1478-7547-7-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2688482/
https://www.ncbi.nlm.nih.gov/pubmed/19416529
http://dx.doi.org/10.1186/1478-7547-7-9

Ejemplares similares